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Abstract: On-site therapeutic drug monitoring (TDM) is important for providing a quick and accurate
dosing to patients in order to improve efficacy and minimize toxicity. Aminoglycosides such as
amikacin, gentamicin, and tobramycin are important antibiotics that have been commonly used
to treat infections of chronic bacterial infections in the urinary tract, lung, and heart. However,
these aminoglycosides can lead to vestibular and auditory dysfunction. Therefore, TDM of
aminoglycosides is important due to their ototoxicity and nephrotoxicity. Here, we have developed a
hot embossed poly (methyl methacrylate) (PMMA) microfluidic device featuring an electrokinetic
size and mobility trap (SMT) to purify, concentrate, and separate the aminoglycoside antibiotic drugs
amikacin, gentamicin, and tobramycin. These drugs were separated successfully from whole blood
within 3 min, with 30-fold lower detection limits compared to a standard pinched injection. The limit
of detections (LOD) were 3.75 µg/mL for gentamicin, 8.53 µg/mL for amikacin, and 6.00 µg/mL for
tobramycin. These are sufficient to cover the therapeutic range for treating sepsis of 6–10 µg/mL
gentamicin and tobramycin and 12–20 µg/mL of amikacin. The device is simple and could be mass
produced via embossing or injection molding approaches.
Keywords: therapeutic drug monitoring (TDM); aminoglycosides; size and mobility traps (SMT)
1. Introduction
Personalized medicine requires healthcare customization with medical practices, treatments,
decisions, or products specific for each patient. It is most commonly associated with diagnostic
testing to detect the early onset for a change in health state. When applied to personalized therapy,
it involves choosing medication based on the patient’s genetic content to identify the correct drug
for treatment [1] and therapeutic drug monitoring (TDM) to ensure the correct dosing period
and optimum concentration to minimize toxicity and improve efficacy [2,3]. TDM requires the
monitoring of blood/plasma concentrations and is important when there is a narrow therapeutic
range. TDM has been proven to progress anticancer therapies, such as methotrexate [4], as well
as in new targeted anticancer agents, such as nilotinib, imatinib, sunitinib, dasatinib, lapatinib,
and sorafenib [5], and is critical for immunospuressants [6]. TDM also shows benefits for a wide array
of drugs, particularly antibacterials, anticonvulsants, antidepressants, antiretrovirals, antipsychotics,
and β-lactam antibiotics [7]. There are a range of methods which can be used to conduct TDM,
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but it is typically carried out in a laboratory by using liquid chromatography mass spectrometry
and immunoassays [8].
For some applications of TDM, there is a desire to either be able to test at-home, such as for
patients receiving treatment for chronic conditions, or for a rapid and quick response to enable quicker
and more efficient treatment. The most well-known example of TDM is measuring blood glucose levels
such that a diabetic can self-dose the correct amount of insulin. There are now many different blood
glucose analyzers available on the market for rapid on-site testing; however, these are predominantly
based on either an antibody or an immunoassay. For targets where there is insufficient specificity in
these approaches, they are usually analysed with a high resolution separation, which is much harder
to miniaturise than an immunoassay. This capability has been recently demonstrated through the
introduction of a portable electrophoretic device, Medimate [9], which can measure lithium levels
in blood. The Medimate is an example of a point-of-care (POC) device based on the micro total
analysis system (µTAS) concept [10]. A µTAS offers the possibility to integrate multiple procedures in
a portable, low-cost platform which is simple to utilize without affecting the results. TDM of lithium
with Medimate has been studied and recently deemed to be clinically useful [11] and is appropriate for
self-testing [12]. While the Medimate device is an impressive and important development for the field,
lithium is well-separated from other matrix components in the blood, and has a high therapeutic range,
making detection relatively simple. Other µTAS devices applicable to TDM have been developed for
glutathione [13], creatinine [14], and β-hydroxybutyrate (βHB) [15].
One of the main impediments in developing a µTAS is the complexity and size of the
instrumentation required for the on-site analysis, and for at-home monitoring, it needs to be fully
automated, simple to use, easy, and low-cost to make. Recently, Shallan et al. [16] developed a
microfluidic device featuring two nanojunctions with different pore sizes to create a size and mobility
trap (SMT) to purify and concentrate small molecules prior to an integrated electrophoretic separation.
Significantly, the nanojunctions were created by dielectric breakdown after the device containing
easier-to-fabricate micron-sized channels was bonded, providing a simpler pathway to commercial
manufacture. The potential of the device for TDM was demonstrated with the determination of
the antibiotic ampicillin from whole blood within 5 min. However, this device was fabricated in
Polydimethylsiloxane (PDMS) where large-volume production is not possible through hot embossing
or injection molding. Li et al. [17] developed a similar device incorporating two commercially
manufactured nanoporous membranes for the concentration and monitoring of albumin in urine
as a marker of albuminurea. While functional, the pore sizes were too large for small molecule
pharmaceuticals, and the additional fabrication steps to incorporate the two different membranes
would significantly increase the cost of the device.
Here, a microfluidic device with an SMT feature created by dielectric breakdown was fabricated
in PMMA instead of PDMS because of the well-known ability of hot embossing or injection molding in
this material [18]. We demonstrate that similar nanojunctions can be created in PMMA using controlled
dielectric breakdown and that a device with two different sized nanojunctions can be used for the
analysis of aminoglycoside antibiotic drugs in whole blood.
2. Experimental Section
2.1. Materials and Chemicals
All solutions were prepared using Milli-Q water (18 MΩ, Millipore, North Ryde, Australia).
PDMS (Sylgard 184) elastomer and curing agent were purchased from Dow Corning (Michigan,
MI, USA). Potassium thiocyanate (KSCN) was purchased from AJAX Chemicals (Sydney, Australia).
5(6)-Carboxy-X-rhodamine (ROX), R-phycoerythrin (RPE), fluorescein, fluorescamine, bovine serum
albumin (BSA), Ferric chloride (FeCl3), aminoglycoside antibiotics (gentamicin, amikacin and
tobramycin), hexadimethrine bromide (HDMB), hydroxypropyl methylcellulose (HPMC), sodium
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tetraborate, di-sodium hydrogen phosphate, and sodium phosphate monobasic for buffer preparation
were purchased from Sigma-Aldrich (Sydney, Australia).
2.2. Sample Preparation
Fluorescamine was prepared in acetone to obtain 3 mg/mL as a stock solution. BSA was prepared
in Milli-Q water at a concentration of 2 mg/mL and then labelled with fluorescamine at a ratio 3:1
in borate buffer at pH 9. ROX and fluorescein were prepared in Milli-Q water to get 25 µg/mL
and 200 µg/mL solutions, respectively. KSCN and FeCl3 were prepared in Milli-Q water to obtain
2.5 M and 25 mM, respectively. Aminoglycosides antibiotics (gentamicin, amikacin, and tobramycin)
stock solutions were prepared in Milli-Q water at a concentration of 500 µg/mL. These were then
labelled with fluorescamine at a ratio of 3:1 in borate buffer at pH 9. Whole blood samples from a
healthy volunteer were collected under the guidelines by the Tasmanian Health and Medical Human
Research Ethics Committee, Office of Research Services, University of Tasmania (Ethics Approval Ref
is H0016575) and spiked with aminoglycosides drugs (amikacin, gentamicin, and tobramycin) (stock
solution) in a ratio of 10:0.1 to obtain different concentrations (2, 5, 10, 15, 20 µg/mL). The mixture was
then labelled with 20 µL fluorescamine in 20 µL borate buffer pH = 9.
2.3. Fabrication of Microfluidic Device
All microfluidic devices were created on a 75 mm × 50 mm × 1.5 mm piece of PMMA (RS
Components, Melbourne, Australia) using the following procedures, with a schematic shown in
Figure S1. First, the negative template of the device was fabricated in SU-8 using previously described
processes [19,20]. Then, PDMS mixed at 5:1 (w/w) was degassed, placed on the SU-8 template,
and then heated in an oven at 70 ◦C for at least 12 h. The positive PDMS stamp was then removed from
the PMMA template and thermally aged in an oven at 250 ◦C for 30 min. The aged PDMS template
was used to hot emboss the PMMA channel plates (1.5 mm × 50 mm × 75 mm) as follows: the blank
PMMA plate and PDMS positive master were placed between two 100 mm × 100 mm × 6 mm glass
plates and put into a hot embosser (MTP-8, Tetrahedron, San Diego, CA, USA). Four steps were used
in the embossing process: Step 1: temperature increased to 130 ◦C at a rate of 92 ◦C /min, at a pressure
of 100 lbs; Step 2: increasing the pressure up to 380 lbs at a rate of 75 lbs/min at the temperature of
130 ◦C, and hold for 20 min; Step 3: the temperature was reduced at a rate of 15 ◦C /min until 60 ◦C
at 380 lbs; Step 4: the pressure was released, and the embossed device removed. The hot embossed
PMMA device was then sealed with single-sided adhesive tape (Tesa SE, Charlotte, NC, USA), with the
device’s microchannels placed downward on 1mm thick stainless steel plates. The assembly was then
fed into the officer laminator (Peach 3500, Peach, Switzerland) at a 20 ◦C temperature, speed 5 for four
passes, with 90 degree clockwise rotation at each pass.
2.4. Creation of Nanojunctions by Controlled Dielectric Breakdown
The microfluidic device is hybrid PMMA/adhesive tape with the complete microchip shown in
Figure 1a and a zoomed in image of the offset double V in Figure 1b. All microchannels had a 50 µm
depth. The separation channel was 50 µm wide and the V channels were 500 µm. The hot embossed
double-V PMMA device was used to create the SMT through the formation of nanojunctions in the
100 µm gap between the tips of the V-channels and the separation channel. This gap distance was
selected instead of 20 µm [21] or 40 µm [22] reported in the literature, to allow for a lengthened use of
higher voltages during the extraction and purification stages without inducing secondary breakdown.
The 500 µm offset distance between the tips of the Vs permitted the two nanojunctions to connect and
generate the SMT. The separation channel length was 60 mm and the effective length from the first
nanojunction (injection point) to the detection point was 30 mm.
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food dye. Scale bar = 10 mm. (b) Zoomed in microscope image of the offset double-V channel filled 
with green food dye (white box in panel a). Scale Bar = 100 µm. (c) Schematic of the microfluidic 
device (dimension not to scale) indicating voltages and terminating current used for generation of the 
extraction nanojunction and (d) the desalting nanojunction. (e) Injection voltages (60 s) to extract, 
concentrate, and desalt injected plug (blue) of small molecules (ROX and fluorescein). (f) Separation 
voltages (180 s) for electrophoretic separation. Buffer (B), Buffer Waste (BW), Sample (S), and Sample 
Waste (SW). 
2.5. Microdevice Operation 
After nanojunction creation, the sample V-channel (S) was filled with sample solution using an 
autopipette. The separation channel was filled with 100 mM phosphate buffer, 0.5% HPMC, or 0.1 % 
of HDMB at pH 11.5, while the V-channel sample waste (SW) was filled with 10 mM phosphate 
buffer, pH 11.5, similar to those reported by Shallan et al. The extraction and separation voltages were 
applied using external electrodes for each reservoir, as shown in Figure 1e,f.  
Visualization of ion enrichment/depletion was conducted using a Nikon high-definition colour 
CCD camera head (Digital Sight DS-Fi1c, Nikon, Japan) operated with NIS-Elements BR 3.10 software 
(Melville, NY, USA) mounted on an inverted fluorescence microscope (Ti-U, Nikon, Tokyo, Japan). 
Multiband pass excitation (λex at 390, 482, 563, and 640 nm) and emission (λem at 446, 523, 600, and 
677 nm) filters (Semrock, Rochester, NY, USA) were used for all the experiments. A photomultiplier 
Figure 1. (a) Photograph image of the double-V hybrid PMMA/adhesive tape device filled with green
food dye. Scale bar = 10 mm. (b) Zoomed in microscope image of the offset double-V channel filled
with green food dye (white box in panel a). Scale Bar = 100 µm. (c) Schematic of the microfluidic
device (dimension not to scale) indicating voltages and terminating current used for generation of
the extraction nanojunction and (d) the desalting nanojunction. (e) Injection voltages (60 s) to extract,
concentrate, and desalt injected plug (blue) of small molecules (ROX and fluorescein). (f) Separation
voltages (180 s) for electrophoretic separation. Buffer (B), Buffer Waste (BW), Sample (S), and Sample
Waste (SW).
To make the nanojunctions, the separation channel and V-channel sample (S) were filled with the
breakdown electrolyte, consisting of 10 mM phosphate buffer, pH 11, while the V-channel sample waste
(SW) was filled with 100 mM phosphate buffer, pH 7. The nanochannels were cr ated by applying
a high voltage of 4000 V ver 100 µm (40 V/µm, which is above the dielectric strength of PMMA
36 V/µm [23]) to the V-sample (S) channel or sample waste (SW) channel whilst the separation channel
was kept grounded, s shown in Figure 1c,d. The current limi was varied from 0.1 µA to 5 µA by
utilizing an in-house djustable power supply, controlled by the LabView HV V.6 program (National
Instrument, Austin, TX, USA), which term nated the voltage once the current limit was achieved.
The current limits were chosen to allow the transport of different sized mo cules. The V-channels
and the separation channel were then refill with th exper mental solutions after cleaning usi g
illi-Q water.
2.5. Microdevice Operation
After nanojunction creation, the sample V-channel (S) was filled with sample solution using an
autopipette. The separation channel was filled with 100 mM phosphate buffer, 0.5% HPMC, or 0.1% of
HDMB at pH 11.5, while the V-channel sample waste (SW) was filled with 10 mM phosphate buffer,
pH 11.5, similar to those reported by Shallan et al. The extraction and separation voltages were applied
using external electrodes for each reservoir, as shown in Figure 1e,f.
Visualization of ion enrichment/depletion was conducted using a Nikon high-definition colour
CCD camera head (Digital Sight DS-Fi1c, Nikon, Japan) operated with NIS-Elements BR 3.10 software
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(Melville, NY, USA) mounted on an inverted fluorescence microscope (Ti-U, Nikon, Tokyo, Japan).
Multiband pass excitation (λex at 390, 482, 563, and 640 nm) and emission (λem at 446, 523, 600,
and 677 nm) filters (Semrock, Rochester, NY, USA) were used for all the experiments. A photomultiplier
tube (PMT) (Hamamatsu Photonics KK, Hamamatsu, Japan) was used to perform the quantitative
measurements which was connected to the microscope. An Agilent interface (35900E) connected to
a laptop and operated by Agilent ChemStation for LC software (Agilent Technologies, Waldbronn,
Germany) was used for data acquisition. An in-house four-channel (0–5 kV) dc power supply was
used to apply an electrical potential to each reservoir through a custom designed interface connected
to six platinum electrodes.
3. Results and Discussions
In our previous work, we designed and demonstrated a new electrokinetic device with a
SMT for the concentration and extraction of drugs, followed by their separation by electrophoresis.
Electrophoresis is a separation mode in which ions, molecules, and particles are separated in an electric
field in a conducting liquid medium. The speed of separation can be manipulated by variation of
the liquid media composition, but is generally dependent on the charge and size of the ion/particle.
Electrophoresis is known to be simpler than liquid chromatography, the other most common separation
approach for TDM, and more easily miniaturized for portability. Here, we build on our previous
electrokinetic sample treatment strategy, and implement it in a more manufacturable material.
3.1. Nanojunction Creation and Transport Properties
Previously, Shallan et al. demonstrated the ability to make nanojunctions of different sizes in
PDMS by dielectric breakdown with termination currents from 1–5 µA [16,24]. Different charge
and size analytes, such as labelled proteins (4–10 nm), aromatic compounds (0.5–1.0 nm), and small
inorganic ions (effective hydrated radii of about 0.3 nm) [25], were used to understand whether there
were differences when compared to the previous work in PDMS. The results from these experiments
are summarized in Figure 2.
A single nanojunction was formed after the breakdown using different current limits. When the
termination current was set at 5 µA (Figure 2 top row), the resulted nanojunctions blocked
blood cells (6–8 µm) [24] and RPE (~10 nm in size) [17] from entering the separation channel,
whilst electrophoretic transport of BSA labelled-fluorescamine (2–4 nm) into the separation channel was
observed, with similar results obtained at 3 µA (Figure 2 second row). Reducing the termination current
to 1 µA (Figure 2 third row) blocked the BSA, but allowed the transport of anionic ROX, fluorescein,
and drugs. Previously, the movement of BSA was restricted in PDMS nanojunctions created with a
termination current of 3 µA [24], higher than what was achieved in this work. The different behavior
in the PMMA devices may be related to the difference in surface charge and/or the elasticity between
the two materials. To produce smaller channels, the ionic strength of the breakdown electrolyte was
increased from 10 mM phosphate to 100 mM phosphate. A termination current of 0.1 µA resulted
in restricting the transport of BSA, ROX, fluorescein, and drugs, while still transporting small ions
(thiocyanate) (~0.3 nm) (Figure 2 bottom row). Overall, based on the permeability results of different
sized molecules (Blood cell 4–6 µm, RPE ~10 nm, BSA 2–4 nm, ROX 1 nm, inorganic ions 0.3 nm),
we were able to estimate the size of fabricated nanochannels with this method.
3.2. SMT Implementation
The SMT is based on the preferential electrokinetic transport of ions through the resulting
nanojunctions. The extraction nanojunction was formed by applying a 1 µA termination current
using 10 mM phosphate pH = 11 electrolyte buffer as this allows small ions transport (e.g., ROX)
through the free transport region, while restricting cells and plasma proteins transport (e.g., BSA).
The concentration nanojunction between the separation channel and the V-sample channel was formed
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Red) and restriction of BSA (left); the fourth row shows the restriction of BSA (left) and transport of 
ROX (right); the fifth row shows the restriction of ROX (left) and transport of thiocyanate (left). The 
first four rows used nanochannels created using a breakdown electrolyte of 10 mM phosphate buffer, 
pH = 11, and different terminating currents (5, 3, 1, and 0.1 μA), while the fifth row used a breakdown 
electrolyte of 100 mM phosphate buffer, pH = 7, and a terminating current of 0.1 μA. Images on the 
right show permeability (arrow), while those on the left show blocked transport. Scale Bar = 200 µm. 
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formed with a termination current of 0.1 µA using 100 mM phosphate pH = 7 as this prevents the 
transport of target analytes (e.g., ROX), but permits the small inorganic ions (e.g., Thiocyanate).  
Figure 3 presents the ability and efficacy of the SMTs to extract and concentrate multiple small 
molecules. Figure 3a is a photo taken during the extraction and concentration of fluorescein (MW 332 
Da) and ROX (MW 534.60 Da) in the separation channel. Figure 3b shows the separation of fluorescein 
and ROX immediately after switching the voltages from extraction and concentration to separation. 
3C is the fluorescence trace collected using a PMT positioned 30 mm from the double-V intersection. 
These experiments show highly efficient separations of both fluorescein and ROX, with efficiencies 
Figure 2. Screen shots showing the transport (right column) and restriction (left column) of different
molecules through nanochannels created under different conditions. The top row shows the restriction
of Blood Cells (left) and transport of BSA (blue, right); the second row shows the restriction of PDMS
(red, left) and t e tr sport of BSA (right); the third row shows the ra port of ROX (right, Red)
and restriction of BSA (left); the fourth row shows the restriction of BSA (left) and transport of ROX
(right); the fifth row shows the restriction of ROX (left) and transport of thiocyanate (left). The first four
rows used nanochannels created using a breakdown electrolyte of 10 mM phosphate buffer, pH = 11,
and different terminating currents (5, 3, 1, and 0.1 µA), while the fifth row used a breakdown electrolyte
of 100 mM phosphate buffer, pH = 7, and a terminating current of 0.1 µA. Images on the right show
permeability (arrow), while those on the left show blocked transport. Scale Bar = 200 µm.
Figur 3 presents the ability and efficacy of the SMTs to extract and concentrate multiple small
molecules. Figure 3a s a phot taken during the extraction and concentration f fluorescein (MW 332
Da) and ROX (MW 534.60 Da) in the separation channel. Figure 3b shows the separation of fluorescein
and ROX immediately after switching the voltages from extraction and concentration to separation.
3C is the fluorescence trace collected using a PMT positioned 30 mm from the double-V intersection.
These experiments show highly efficient separations of both fluorescein and ROX, with efficiencies
of 414,000 and 203,000 plates/m, respectively. The relative standard deviation (RSD%) = 11.5 % for
fluorescein and 4.5 % for ROX (n = 3 devices).
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set at −100, −700, −500, and +500 V (for the injection) and −300, +220, +2000, and −400 V (for the 
separation) for reservoirs B, S, BW, and SW, respectively. 
3.3. Extraction and Analysis of Aminoglycosides in Whole Blood 
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for achieving this was demonstrated by the detection of the three aminoglycoside drugs gentamicin, 
amikacin, and tobramycin. after derivatization with fluorescamine using both the double-V device 
and a normal cross channel design with pinched injection [26]. Figure 4 shows the separation of a 
standard mixture of these three labeled aminoglycosides in both the double-V device and a normal 
cross-design with pinched injection. It can be seen from the figure that the peaks in the double-V 
design are significantly higher than in the cross-device, demonstrating the concentration ability of 
the device. A 30-fold enhancement factor was achieved without any significant broadening of the 
peaks.   
The other function of the SMT is to purify the sample. This can be seen in Figure 5 and Figure S2a, 
which show the separation of blood spiked with the aminoglycosides and then labelled with 
Figure 3. Screen shots showing (a) extraction, trapping, and (b) separation. Scale Bar = 100 µm.
(c) Detection of small molecules (fluorescein and ROX). Current limit was set at 1µA for the right
side and 0.1 µA for the left side. BGE in the separation channel is 100 mM phosphate buffer, pH 11.5,
with 0.5 % HPMC to suppress the EOF and 0.1% HDMB to reverse the EOF, while in the left V-sample
waste channel, 10 mM phosphate buffer, pH 11.5, was used without HPMC. Applied voltages were
set at −100, −700, −500, and +500 V (for the injection) and −300, +220, +2000, and −400 V (for the
separation) for reservoirs B, S, BW, and SW, respectively.
3.3. Extraction and Analysis of Aminoglycosides in Whole Blood
The purpose of the SMT is to purify and concentrate anionic pharmaceuticals with a low molecular
weight (<1000 Da) from biologica fluids uch as b ood. The applicability of the PMMA-embossed
device for achieving this was demonstrated by the detection of the three aminoglycoside drugs
gentamicin, amikacin, and tobramycin. after derivatization with fluorescamine using both the double-V
device and a normal cross channel design with pinched injection [26]. Figure 4 shows the separation of
a standard mixture of these three labeled aminoglycosides in both the double-V device and a normal
cross-design with pinched injection. It can be seen from the figure that the peaks in the double-V
design re significantly higher than in the cross- evic , demonstrating the concentra ion ability of the
device. A 30-f ld enhancem nt factor was achieved without any significant broadening of the peaks.
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fluorescamine. The BGE in the V- sample waste channel was 10 mM phosphate buffer, pH 11.5, while 
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voltages for SMT were −100, −700, −500, and +500 V for 60 s and for separation were −300, +220, +2000, 
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channels were filled with 100 mM phosphate buffer, pH 11.5, with 0.5% HPMC. Applied voltages for 
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Electropherogram show the comparis n of SMT ( ed trace) with pinch d i jection
(black trace) of 5 ppm Gentamicin, 20 ppm Amikacin, and 10 pm Tobramycin after lli
fl i . The BGE in the V- sample waste channel was 10 mM osphate buffer, pH 11.5,
while in the separation channel, it was 100 mM phosphate buffer, pH 1.5, with 0.5% . li
lt s f r ere 1 0, −700, −500, and +500 V for 60 s and for separation were −300, +22 ,
+2000, and −400 V at reservoirs B, S, BW, and SW, respectively. For pinched injection (cross-channel),
all channels were filled with 100 mM phosphate buffer, pH 11.5, with 0.5% HPMC. Applied voltages
for injection were −100, −400, −300, and +400 V at B, S, BW, and SW reservoirs, respectively,
and separation voltages were −200, +400, +1500, and +400 V at B, S, BW, and SW reservoirs, respectively.
The other function of the SMT is to purify the sample. This can be seen in Figure 5 and
Figure S2a, which show the separation of blood spiked with the aminoglycosides and then labelled
with fluorescamine. The cross device provides a clean peak for tobramycin, but interferences are
observed for gentamicin and amikacin. This is due to fluorescamine reacting with all primary
amines, including those on drugs, proteins, amino acids, etc., found in the blood. In contrast,
the double-V device containing the SMT provides clean separations due to the removal of some
of the interferences, most likely the larger proteins. Some endogenous small molecules are still
observed in the SMT, but these are well-resolved from the target drugs in this instance, allowing full
and complete quantitation of the three aminoglycosides. The device shows high recovery efficiencies
for the three drugs (Gentamicin 92%, Amikacin 98%, and Tobramycin 98%) and there were no clogging
cases observed during the analysis.
The linear calibration curve of the Aminoglycosides (gentamycin, amikacin, and tobramycin)
from blood is shown in Figure S2b. The LOD (signal to noise level of three) was 3.75 µg/mL for
gentamicin, 8.53 µg/mL for amikacin, and 6 µg/mL for tobramycin, and they are linear to 2–20 µg/mL,
which covers the therapeutic range for treating sepsis of 6–10 µg/mL gentamicin and tobramycin and
12–20 µg/mL of amikacin [27].
In comparison to current methods for these aminoglycosides, they can be analyzed by immuno-
assays, such as the Fluorescence Polarization Immunoassay (FPIA), Radioimmunoassay (RIA),
and Enzyme-linked Immunosorbent assay (ELISA). These assays have limitations. The FPIA assay
has a good reproducibility, is comparatively cheap, and is labor non-intensive [27]. Additionally,
FPIA is fully automated, but demands an IMx FPIA analyzer [28] that is relatively expensive. RIA was
successfully used to determine the aminoglycosides in biological samples, but it has problems related
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to handling radioactivity and the equipment is costly [29]. The ELISA system labeling with primary
antibodies is time-consuming and the labeling of the primary antibody from one experiment to
another is not flexible [30]. HPLC (High Performance Liquid Chromatography) is a sensitive method
for conducting the aminoglycosides, but requires expensive instruments [31] and shortening the
separation time is required [32]. By Higher Performance Liquid Chromatography (HPLC), the LOQ
for tobramycin is as low 0.05 µg/mL using 200 µL of plasma [33]; however, these low levels are not
necessary given the therapeutic range of aminoglycosides. When monitoring preterm infants, it is more
profitable to use smaller volumes of sample, which should not overtake 75 µL [34]. Here, the suggested
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4. Conclusions
We have demonstrated an integrated hot embossed PMMA featuring an SMT device for desalting,
on-chip extraction, and concentration. The hot embossed PMMA controlling dielectric breakdown
enabled nanojunctions’ pore size tuning. This method permitted the analysis of aminoglycosides as
negatively charged drugs which were off-chip spiked with on-site finger prick blood (~20–100 µL)
and labelled with fluorescamine. The nanojunctions created using dielectric breakdown are achieved
simply and quickly, and the electric field controlling pore size permits their integration without
increasing the fabrication cost. The device allows a simple operation and does not rely on valves or
pumps. With integrated reagents (dried fluorescamine and liquid electrolytes) and a hand-held reader,
this would create a fully-portable screening device for POC analysis of therapeutics.
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